Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Ginkgo Bioworks Holdings Inc (DNA)

172 + Investors. Track Smart Money conviction in DNA. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -3
Streak
1Q ▼
Buyers last Q
52%

Smart Money Signals — DNA

Based on 174 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their DNA positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🔻

Below peak — only 53% of 3.0Y high

53% of all-time peak
Only 174 funds hold DNA today versus a peak of 326 funds at 2023 Q4 — just 53% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.
📶

Steady growth — +5% more funds vs a year ago

fund count last 6Q
+9 new funds entered over the past year (+5% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 52% buying

83 buying76 selling
Last quarter: 83 funds bought or added vs 76 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~31 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 35 → 32 → 31 → 31. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

60% of holders stayed for 2+ years

■ 60% conviction (2yr+) ■ 21% medium ■ 18% new
105 out of 174 hedge funds have held DNA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares -3%, value -34%

Value
-33%
Shares
-2%
Last quarter: funds added -3% more shares while total portfolio value only changed -34%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
➡️

Steady discovery — ~31 new funds/quarter

28 → 35 → 32 → 31 → 31 new funds/Q
New funds entering each quarter: 35 → 32 → 31 → 31. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 68% veterans vs 23% newcomers

■ 68% veterans ■ 9% 1-2yr ■ 23% new
Entry-cohort mix of 178 holders: 121 (68%) are 2+ year veterans, 16 entered 1–2 years ago, and 41 (23%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 40% AUM from top-100 funds

40% from top-100 AUM funds
40 of 173 holders are among the 100 largest funds by AUM, controlling 40% of total institutional value in DNA. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
1.2
out of 10
Low Exit Risk
Exit risk score 1.2/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — DNA

In 2026 Q1, 83 hedge funds were net buyers of DNA (31 opened a new position, 52 added to an existing one), while 76 reduced or exited (42 trimmed, 34 sold completely) — a 52% buyer ratio, indicating a slight buying edge. 40% of total institutional value in DNA is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: -3 funds (more exits than new entries). Total institutional holders: 174.

Hedge Fund Ownership: DNA

How many hedge funds hold DNA — quarterly history vs. share price
Quarterly hedge fund ownership of DNA vs. share price

Market Analysis: DNA

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: DNA

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Ginkgo Bioworks Holdings Inc (DNA) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much DNA has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 49d ago
DNA
-30.2%
XLV
-24.6%

DNA outperformed XLV by -5.6% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 4d ago
DNA
+1.9%
XLV
-4.9%

Since the filing became public, DNA outperformed XLV by +6.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

16 top-rated funds 0 high-conviction
Consensus
5.3
/ 10
breadth
×
Elite
0.3
/ 10
conviction
Hedge Fund Positioning: DNA
2026 Q2 Stats Unlock in 1 days 172 + Investors

Track Smart Money conviction in DNA. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 172 176 -2.27%
13F Shares 33M 34M -2.57%
Total Value $198M $299M -33.76%
New Positions 30 31 -1
Increased Positions 50 53 -3
Closed Positions 34 30 +4
Reduced Positions 42 41 +1
Total Calls 3 9 -66.67%
Total Puts 2 5 -60.0%
PUT/CALL Ratio 0.67 0.56 Bullish

Statistics: DNA

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

172 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in DNA. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 DNA holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Anchorage Capital Group, L.L.C. 3.84% 1,746,363 $17.3M
2 Balance Capital Partners L.P. 1.42% 199,009 $2.0M
3 Forbes J M & Co LLP 0.78% 999,911 $9.9M
4 Prescott Group Capital Management, L.L.C. 0.46% 541,845 $5.4M
5 Strategic Advocates LLC 0.26% 6,737 $67K
6 Erste Asset Management GmbH 0.20% 2,536,939 $25.9M
7 Coastal Bridge Advisors, LLC 0.17% 276,817 $2.7M
8 Viking Global Investors LP 0.10% 3,577,128 $35.4M
9 Green Alpha Advisors, LLC 0.09% 13,546 $134K
10 Allen Operations LLC 0.09% 61,951 $614K
11 Numerai GP LLC 0.08% 104,602 $1.0M
12 Sb Investment Advisers (uk) Ltd 0.08% 610,729 $6.1M
13 Dynamic Technology Lab Private Ltd 0.08% 34,996 $347K
14 Caxton Associates LLP 0.03% 154,647 $1.5M
15 Inspire Investing, LLC 0.03% 70,246 $696K
16 Shay Capital LLC 0.03% 44,842 $444K
17 Axq Capital, LP 0.03% 26,477 $262K
18 Susquehanna Portfolio Strategies, LLC 0.03% 176,231 $1.7M
19 Boston Standard Wealth Management, LLC 0.02% 15,165 $165K
20 Baillie Gifford & Co 0.02% 2,391,649 $23.7M
21 Algert Global LLC 0.02% 180,060 $1.8M
22 Casdin Capital, LLC 0.02% 36,493 $362K
23 Pfizer Inc 0.02% 2,928 $30K
24 Exchange Traded Concepts, LLC 0.02% 358,783 $3.6M
25 a16z Capital Management, L.L.C. 0.01% 108,568 $1.1M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Ginkgo Bioworks Holdings Inc (DNA)

What does the Smart Money Trend signal show for DNA?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their DNA positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for DNA?

Slight buying edge — 52% buying: Last quarter: 83 funds bought or added vs 76 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for DNA holders?

Elite ownership — 40% AUM from top-100 funds: 40 of 173 holders are among the 100 largest funds by AUM, controlling 40% of total institutional value in DNA. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held DNA?

60% of holders stayed for 2+ years: 105 out of 174 hedge funds have held DNA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Ginkgo Bioworks Holdings Inc (DNA) following the 2026 Q2 hedge fund 13F filings?

As of today, DNA has moved +1.9% since the 2026 Q2 13F filing date (August 14, 2026), compared to -4.9% for the XLV sector ETF — an outperformance of +6.8%. Since the quarter end (June 30, 2026), DNA has gained -30.2% vs -24.6% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →